+7 (777) 001 44 99
Қазақша
Русский
English
Қазақша
Русский
English
ПОДЕЛИТЬСЯ
A single dose -- rather than the recommended three -- of a vaccine against the sexually transmitted disease HPV may be enough to ward off cervical cancer, AFP reports citing researchers. The findings may lead to simpler delivery and lower costs, possibly increasing the number of young people who get vaccinated, said the report in the journal Cancer Prevention Research. The HPV vaccine is recommended for girls and boys before they become sexually active, but US research from 2012 showed that only one third of US female teens and fewer than seven percent of US boys got the recommended three doses. "Our findings suggest promise for simplified vaccine administration schedules that might be cheaper, simpler, and more likely to be implemented around the world," said Mahboobeh Safaeian, an investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Maryland. The study focused on a population of nearly 7,500 women aged 18-25 in Costa Rica. Although all were supposed to get the recommended three doses of the HPV vaccine at different times, about 20 percent of participants did not. So researchers analyzed blood samples from a group of 78 who got one dose, compared to groups of 120 to 192 that received two or three doses as planned. They found that all the women in all three groups had antibodies against virulent strains of HPV, known as 16 and 18. These antibodies persisted in their blood for up to four years, which is about as long as researchers have expected the vaccine to be effective. The levels of antibodies also appeared stable over time, even though they were slightly lower in the single dose group, suggesting "these are lasting responses," said the study. The vaccine used in the study was Cervarix, made by the British pharmaceutical giant GlaxoSmithKline. "GSK is continuing to review findings from this trial and is committed to ensuring regulatory authorities and public health officials have access to this information," a company spokesman told AFP. Study authors said antibody responses after a single dose have not been evaluated for Gardasil, the quadrivalent HPV vaccine made by Merck that is more widely used in the United States and many other countries. More research is needed before any formal changes can be decided, but Safaeian said the findings could have far-reaching impact in low income nations. "Vaccination with two doses, or even one dose, could simplify the logistics and reduce the cost of vaccination, which could be especially important in the developing world, where more than 85 percent of cervical cancers occur, and where cervical cancer is one of the most common causes of cancer-related deaths," she said. HPV can cause oral, anal, and cervical cancer. According to the World Health Organization, cervical cancer is the second most common cancer in women worldwide, and causes 500,000 new cases and 250,000 deaths each year. By Kerry Sheridan
A single dose -- rather than the recommended three -- of a vaccine against the sexually transmitted disease HPV may be enough to ward off cervical cancer, AFP reports citing researchers.
The findings may lead to simpler delivery and lower costs, possibly increasing the number of young people who get vaccinated, said the report in the journal Cancer Prevention Research.
The HPV vaccine is recommended for girls and boys before they become sexually active, but US research from 2012 showed that only one third of US female teens and fewer than seven percent of US boys got the recommended three doses.
"Our findings suggest promise for simplified vaccine administration schedules that might be cheaper, simpler, and more likely to be implemented around the world," said Mahboobeh Safaeian, an investigator in the Division of Cancer Epidemiology and Genetics at the National Cancer Institute in Maryland.
The study focused on a population of nearly 7,500 women aged 18-25 in Costa Rica. Although all were supposed to get the recommended three doses of the HPV vaccine at different times, about 20 percent of participants did not.
So researchers analyzed blood samples from a group of 78 who got one dose, compared to groups of 120 to 192 that received two or three doses as planned.
They found that all the women in all three groups had antibodies against virulent strains of HPV, known as 16 and 18.
These antibodies persisted in their blood for up to four years, which is about as long as researchers have expected the vaccine to be effective.
The levels of antibodies also appeared stable over time, even though they were slightly lower in the single dose group, suggesting "these are lasting responses," said the study.
The vaccine used in the study was Cervarix, made by the British pharmaceutical giant GlaxoSmithKline.
"GSK is continuing to review findings from this trial and is committed to ensuring regulatory authorities and public health officials have access to this information," a company spokesman told AFP.
Study authors said antibody responses after a single dose have not been evaluated for Gardasil, the quadrivalent HPV vaccine made by Merck that is more widely used in the United States and many other countries.
More research is needed before any formal changes can be decided, but Safaeian said the findings could have far-reaching impact in low income nations.
"Vaccination with two doses, or even one dose, could simplify the logistics and reduce the cost of vaccination, which could be especially important in the developing world, where more than 85 percent of cervical cancers occur, and where cervical cancer is one of the most common causes of cancer-related deaths," she said.
HPV can cause oral, anal, and cervical cancer.
According to the World Health Organization, cervical cancer is the second most common cancer in women worldwide, and causes 500,000 new cases and 250,000 deaths each year.
By Kerry Sheridan
